This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Quotient Dividend

Dividend criteria checks 0/6

Quotient does not have a record of paying a dividend.

Key information

n/a

Dividend yield

n/a

Payout ratio

Industry average yield	1.8%
Next dividend pay date	n/a
Ex dividend date	n/a
Dividend per share	n/a
Earnings per share	-US$5.89
Dividend yield forecast in 3Y	n/a

Recent dividend updates

No updates

Recent updates

Quotient expands MosaiQ Innovator's Circle

Aug 24

Quotient teams up with InfYnity Biomarkers to advance infectious disease testing

Jul 12

Analysts Just Shaved Their Quotient Limited (NASDAQ:QTNT) Forecasts Dramatically

Feb 10

Stability and Growth of Payments

Fetching dividends data

Stable Dividend: Insufficient data to determine if QTNT.Q's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if QTNT.Q's dividend payments have been increasing.

Dividend Yield vs Market

Quotient Dividend Yield vs Market

How does QTNT.Q dividend yield compare to the market?
Segment	Dividend Yield
Company (QTNT.Q)	n/a
Market Bottom 25% (US)	1.5%
Market Top 25% (US)	4.7%
Industry Average (Medical Equipment)	1.8%
Analyst forecast in 3 Years (QTNT.Q)	n/a

Notable Dividend: Unable to evaluate QTNT.Q's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate QTNT.Q's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as QTNT.Q has not reported any payouts.

Discover strong dividend paying companies

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

This company listing is no longer active

Quotient Dividend

Dividend criteria checks 0/6

Key information

Recent dividend updates

Recent updates

Quotient Limited Filed for Bankruptcy

Quotient Limited(OTCPK:QTNT.F) dropped from NASDAQ Composite Index

Quotient Limited Announces Resignation of Franz Walt as Director

Quotient Announces Intent to Voluntary Delist from the Nasdaq Global Market

Price target increased to US$90.00

High number of new directors

Quotient Limited Announces the Retirement of Brian McDonough as Member of the Board of Directors

High number of new directors

High number of new directors

Independent Chairman of the Board recently bought US$140k worth of stock

Quotient Limited Appoints Sophie Bechu as A Director

Quotient expands MosaiQ Innovator's Circle

Consensus EPS estimates fall by 25%

Quotient Receives Non-Compliance Letter from Nasdaq

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Quotient Limited Provides Earnings Guidance for the Fiscal Year Ending March 31, 2023

Quotient Limited to Report Q1, 2023 Results on Aug 09, 2022

Quotient Limited, Annual General Meeting, Oct 31, 2022

Quotient Limited Announces Executive Changes

Quotient teams up with InfYnity Biomarkers to advance infectious disease testing

Consensus estimates of losses per share improve by 40%

Price target decreased to US$2.75

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Quotient Limited Provides Earnings Guidance for the Fiscal Year 2023

Quotient Limited to Report Q4, 2022 Results on Jun 22, 2022

Quotient Limited and Theradiag Announce Partnership to Advance Autoimmune Disease Diagnostics

Quotient Receives Non-Compliance Letter from Nasdaq

Quotient Receives Non-Compliance Letter from Nasdaq

Quotient Limited Appoints Thomas Aebischer to Quotient Board of Directors, Effective as of May 1, 2022

Quotient Limited Appoints Manuel O. Méndez as Director

Price target increased to US$7.67

Quotient Limited Appoints Thomas Aebischer to Board of Directors, Effective as of May 1, 2022

Independent Chairman of the Board recently bought US$78k worth of stock

Price target decreased to US$7.75

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Analysts Just Shaved Their Quotient Limited (NASDAQ:QTNT) Forecasts Dramatically

Consensus forecasts updated

Quotient Limited to Report Q3, 2022 Results on Feb 08, 2022

Chief Commercial Officer recently bought US$103k worth of stock

Second quarter 2022 earnings released: US$0.27 loss per share (vs US$0.16 loss in 2Q 2021)

Chief Commercial Officer Jeremy Stackawitz has left the company

First quarter 2022 earnings released: US$0.24 loss per share (vs US$0.32 loss in 1Q 2021)

Price target decreased to US$10.50

Full year 2021 earnings released: US$1.18 loss per share (vs US$1.44 loss in FY 2020)

Quotient Limited Provides Revenue Guidance for the First Quarter and Full Year Ending March 31, 2022

Quotient beats on revenue; issues guidance

Quotient Limited announced that it has received $95 million in funding from Highbridge Capital Management, LLC, CI Global Asset Management, Russell Investments Canada Ltd., Whitebox Advisors, LLC

Chief Operating Officer notifies of intention to sell stock

Quotient Limited announced that it expects to receive $95 million in funding from Highbridge Capital Management, LLC and other investors

Here's Why Quotient (NASDAQ:QTNT) Can Afford Some Debt

A Look At Quotient's (NASDAQ:QTNT) Share Price Returns

Quotient Limited Announces Manuel Mendez as Chief Executive Officer, Effective April 1, 2021

New 90-day low: US$4.92

Chief Operating Officer exercised options and sold US$487k worth of stock

Third quarter 2021 earnings released: US$0.29 loss per share (vs US$0.37 loss in 3Q 2020)

Revenue beats expectations, earnings disappoint

New 90-day low: US$5.04

Quotient EPS beats by $0.01, beats on revenue

Read This Before Selling Quotient Limited (NASDAQ:QTNT) Shares

Quotient Limited to Report Q3, 2021 Results on Feb 01, 2021

Is Quotient (NASDAQ:QTNT) A Risky Investment?

Quotient Limited Announces Resignation of Ed Farrell from His Position as Chief Operating Officer

Quotient operations chief resigns

New 90-day high: US$7.32

Quotient Limited Provides Status Update on the Initial SDS Microarray and MosaiQ Instrument for the US Market

Quotient drops ~7% as FDA requires additional data for regulatory clearance

Quotient (NASDAQ:QTNT) Shareholders Have Enjoyed A 58% Share Price Gain

New 90-day high: US$6.15

Quotient's Disruptive MosaiQ Platform And Its Upcoming Approval

Second quarter 2021 earnings released: US$0.18 loss per share

Revenue beats expectations, earnings disappoint

Quotient EPS beats by $0.16, beats on revenue

Quotient Limited to Report Q2, 2021 Results on Nov 02, 2020

Quotient Limited Receives Receipt of U.S. FDA Emergency Use Authorization or Mosaiq COVID19 Antibody Test